Growth Metrics

Teva Pharmaceutical Industries (TEVJF) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $686.0 million.

  • Teva Pharmaceutical Industries' Income towards Parent Company rose 34326.24% to $686.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $686.0 million, marking a year-over-year increase of 34326.24%. This contributed to the annual value of $1.4 billion for FY2025, which is 17112.35% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Income towards Parent Company stood at $686.0 million, which was up 34326.24% from $428.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Income towards Parent Company ranged from a high of $686.0 million in Q4 2025 and a low of -$2.4 billion during Q4 2023
  • In the last 5 years, Teva Pharmaceutical Industries' Income towards Parent Company had a median value of -$744.5 million in 2021 and averaged -$747.3 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Income towards Parent Company crashed by 11153.42% in 2022, and later skyrocketed by 34326.24% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Income towards Parent Company (Quarter) stood at -$1.1 billion in 2021, then plummeted by 90.51% to -$2.1 billion in 2022, then decreased by 13.53% to -$2.4 billion in 2023, then soared by 88.33% to -$282.0 million in 2024, then surged by 343.26% to $686.0 million in 2025.
  • Its Income towards Parent Company stands at $686.0 million for Q4 2025, versus $428.0 million for Q3 2025 and $274.0 million for Q2 2025.